Soluble Receptor for Advanced Glycation End Products: From Disease Marker to Potential Therapeutic Target

Author(s): Diego Geroldi, Colomba Falcone, Enzo Emanuele

Journal Name: Current Medicinal Chemistry

Volume 13 , Issue 17 , 2006

Become EABM
Become Reviewer


The receptor for advanced glycation end products (RAGE) is a cell-bound receptor of the immunoglobulin superfamily which may be activated by a variety of proinflammatory ligands including advanced glycoxidation end products, S100/calgranulins, high mobility group box 1, and amyloid β-peptide. RAGE has a secretory splice isoform, soluble RAGE (sRAGE), that lacks the transmembrane domain and therefore circulates in plasma. By competing with cell-surface RAGE for ligand binding, sRAGE may contribute to the removal/neutralization of circulating ligands thus functioning as a decoy. Clinical studies have recently shown that higher plasma levels of sRAGE are associated with a reduced risk of coronary artery disease, hypertension, the metabolic syndrome, arthritis and Alzheimers disease. Increasing the production of plasma sRAGE is therefore considered to be a promising therapeutic target that has the potential to prevent vascular damage and neurodegeneration. This review presents the state of the art in the use of sRAGE as a disease marker and discusses the therapeutic potential of targeting sRAGE for the treatment of inflammationrelated diseases such as atherosclerosis, arthritis and Alzheimers disease.

Keywords: receptor for advanced glycation end products, inflammation, neurodegeneration, atherosclerosis, metabolic, syndrome, hypertension, arthritis, Alzheimer's disease, biomarker

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [1971 - 1978]
Pages: 8
DOI: 10.2174/092986706777585013
Price: $65

Article Metrics

PDF: 16